Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial
Aptevo Therapeutics announced a 93% clinical benefit rate for mipletamig in frontline acute myeloid leukemia trial results.
Stocks · News reference
8-K filing — Aptevo Therapeutics Inc. (APVO)
Filed: 2026-09-03 AccNo: 0001193125-26-381098 Size: 185 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Aptevo Reports 93% Clinical Benefit Rate With Mipletamig Triplet in Evaluable Frontline Acute Myeloid Keukemia Patients With TP53 Mutations
Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success
Aptevo Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "TUMOR-ASSOCIATED ANTIGENS AND CD3-BINDING PROTEINS, RELATED COMPOSITIONS, AND METHODS".
https://patentcenter.uspto.gov/applications/18255342/ifw/docs